MedPath

Reducing bilirubin-induced neurological dysfunction in preterm infants: additional use of the Bilirubin:Albumin Ratio in the treatment of hyperbilirubinemia

Not Applicable
Completed
Conditions
Hyperbilirubinemia, bilirubin induced neurological dysfunction
Nervous System Diseases
Neurological dysfunction
Registration Number
ISRCTN74465643
Lead Sponsor
niversity Medical Centre Groningen (UMCG) (The Netherlands)
Brief Summary

Meeting abstracts: 1. van Imhoff, DE; Dijk, PH; Bos, AF, et al. (2007) Dutch thresholds for unconjugated hyperbilirubinemia in preterm infants: when should treatment be started? ACTA PAEDIATRICA 96: 197-197 2. V W van den Belt, M van der Heide, D E van Imhoff, A F Bos, P H Dijk, C V Hulzebos, and Bart Studygroup (2008) IRRADIANCE LEVELS OF PHOTOTHERAPY IN JAUNDICED PRETERM INFANTS. Arch. Dis. Child. 93: p252 2008 results in: http://www.ncbi.nlm.nih.gov/pubmed/18450807 2013 hearing loss results in https://pubmed.ncbi.nlm.nih.gov/23667532/ (added 12/04/2021) 2014 results in: http://www.ncbi.nlm.nih.gov/pubmed/24927259

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
614
Inclusion Criteria

1. Preterm infants born at gestational age less than 32 weeks, either sex
2. Admittance in the first 24 hours of life to a neonatal intensive care unit care centre in the Netherlands

Exclusion Criteria

Major congenital malformations, clinical syndromes and chromosomal abnormalities that affect neurodevelopmental outcome

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<br> Blinded assessment of the participants outcome is performed.<br><br> Primary outcome:<br> 1. Neurodevelopmental outcome at the age of 18 to 24 months using standardised neurological examination will be measured from October 2008 till April 2010<br> 2. Mental- and Psychomotor Developmental Index scores (MDI and PDI: Dutch version of Bayley scales of infant development II) will be measured from October 2008 till April 2010<br>
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath